We hypothesize that in GBM tumors, both Sema3C overexpression and NaVP treatment operate via the same epithelial-to-mesenchymal transition mechanism as was shown in other studies with prostate cancer [32,33]. This evidence concerns the gene SEMA3C and prostate cancer.